Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-09-25
2007-09-25
Spector, Lorraine (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C530S351000
Reexamination Certificate
active
10742372
ABSTRACT:
Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.
REFERENCES:
patent: 5116964 (1992-05-01), Capon et al.
patent: 5703088 (1997-12-01), Sharpe et al.
patent: 5716805 (1998-02-01), Srinivasan et al.
patent: 6043344 (2000-03-01), Jacobs et al.
patent: 6083906 (2000-07-01), Troutt
patent: 6100235 (2000-08-01), Yao
patent: 6191104 (2001-02-01), Spriggs et al.
patent: WO95/18826 (1995-07-01), None
Albrecht et al., “Primary Structure of the Herpesvirus Saimiri Genome,”J. Virol. 66:5047-5058, 1992.
Aarvak, T. et al., “IL-17 is Produced by Some Proinflammatory Th1/Th0 Cells but not by Th2 Cells,”J. of Immuno., 162:1246-1251, 1999.
Bowie et al, “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science 247:1306-1310, 1990.
Chabaud, M. et al., “A T Cell-Derived Proinflammatory Cytokine Produced by the Rheumatoid Synovium,”Arthritis&Rheumatism, 42(5):963-970, 1999.
Fanslow et al., “Regulation of Alloreactivity I Vivo IL-4 and the Soluble IL-4 Receptor,”J. Immunol., 147:535-540, 1991.
Fanslow et al. “Regulation of Alloreactivity in Vivo by a Soluble Form of the Interleukin-1 Receptor,”Science, 248:739-742, 1990.
Frommel and Holzhutter, “An Estimate on the Effect of Point Mutation and Natural Selection on the Rate of Amino Acid Replacement in Proteins,”J. Mol. Evol., 21:233-257, 1985.
GenBank Accession No. H55639.
GenBank Accession No. U31993.
K. Kurasawa et al., “Increased IL-17 production in patients with systemic sclerosis,”Arthritis and Rheumatism, 43(11):2455-2463, 2000.
Matusevicius, D. et al., “Interleukin-17 mRNA Expression in Blood and CSF Mononuclear Cells is Augmented in Multiple Sclerosis,”Multiple Sclerosis, 5:101-104, 1999.
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” inthe Protein Folding Problem and Tertiary Structure Prediction, Mertz and LeGrand, eds. 1994, pp. 491-495.
Nicholas et al., “Gene Expression in Cells Infected with Gammaherpesvirus Saimiri: Properties of Transcripts from Two Immediate-Early Genes,”Virol.179:189-200, 1990.
Pelidou, S.H. et al., “Enhancement of Acute Phase and Inhibition of Chronic Phase of Experimental Autoimmune Neuritis in Lewis Rats by Intranasal Administration of Recombinant Mouse Interleukin 17: Potential Immunoregulatory Role,”Exp. Neuro., 163:165-172, 2000.
Rouvier et al., “CLTA-8, Cloned from an Activated T Cell, Bearing AU-Rich Messenger RNA Instability Sequences, and Homologous to a Herpesvirus Saimiri Gene,”J. Immunol., 150:5445-5456, 1993.
Teunissen, M. et al., “Interleukin-17 and Interferon-γ Synergize in the Enhancement of Proinflammatory Cytokine Production by Human Keratinocytes,”J. of Investigative Dermatology, 111(4):645-649, 1998.
Torrance et al., “Inhibition of Cytokine Activity in Collagen Induced Arthritis,” poster presentation, Mar. 7, 1997.
Trofatter et al., “An Expression-independent Catalog of Genes from Human Chromosome 22,”Genome Res., 5:214-224, 1995.
Wong, C. K., “Elevation of Proinflammatory Cytokine (IL-18, IL-17, IL-12) and Th2 Cytokine (IL-4) Concentrations in Patients with Systemic Lupus Erythematosus,”Lupus, 9:589-593, 2000.
Yao et al., “Herpesvirus Saimiri Encodes a New Cytokine, IL-17, Which Binds to a Novel Cytokine Receptor,”Immunity, 3:811-821, 1995.
Fanslow William C.
Spriggs Melanie K.
Yao Zhengbin
Immunex Corporation
Jiang Dong
Klaniecki James E.
Spector Lorraine
LandOfFree
Methods of treating allergy by administering interleukin-17... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating allergy by administering interleukin-17..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating allergy by administering interleukin-17... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3720931